Treatment Outcomes Of Patients With Serpiginous And Serpiginous-Like Choroiditis

    Abstract

    Treatment Outcomes Of Patients With Serpiginous And Serpiginous-Like Choroiditis

    Gamze Ucan Gunduz, Mehmet Omer Kiristioglu, Ozgur Yalcinbayir, Oner Gelisken, Ahmet Ali Yucel

    Department of Ophthalmology. Uludag University School of Medicine, Bursa, Turkey
OzelJimerHastanesi, Bursa, Turkey

    Purpose. To present the clinical outcomes of different immunomodulatory agents and/or antitubercular therapy (ATT) in patients with serpiginous choroiditis (SC) and serpiginous-like choroiditis (SLC).

    Material and methods. Eighteen eyes of ten patients who were treated with different immunomodulatory agents were retrospectively enrolled in the study. Mean age of the patients was 53,2±12,1 years. Mean follow-up period was 47,4 (±46,8) months.

    Results. Eight of ten patients received steroids and immunmodulatory treatment. If patients had active or latent tuberculosis, they also received ATT. Four patients were in remission with adalimumab. Intravitreal bevacizumab injection was applied to two patients who had choroidal neovascularisation associated with SC.

    Conclusion. As a result, main treatment modalities of SC and SLC are controversial.While corticosteroids are recommended in the acute form of disease, immunomodulatory agents are important to prevent relapses. In case of proven latent or active tuberculosis, ATT has to be added to treatment regimen. Adalimumab may be beneficial to prevent relapses in patients with recalcitrant to conventional immunomodulatory treatment.

    Key words: adalimumab, antitubercular therapy, serpiginous choroiditis, serpiginous-like choroiditis